Parallel Advisors, LLC Immunovant, Inc. Transaction History

Parallel Advisors, LLC

0.0%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$27.51 - $27.51 $0 - $0	0 New	0 $0
Q1 2023 May 20, 2024	BUY	$15.27 - $19.72 $366 - $473	24 New	24 $0
Q3 2022 Nov 10, 2022	BUY	$3.93 - $6.37 $94 - $152	24 New	24 $0
Q1 2022 Apr 28, 2022	SELL	$5.06 - $8.77 $1,932 - $3,350	-382 Closed	0 $0
Q4 2021 Jan 20, 2022	SELL	$7.33 - $9.32 $101,740 - $129,361	-13,880 Reduced 97.32%	382 $3,000
Q1 2021 Apr 23, 2021	BUY	$13.08 - $49.6 $186,546 - $707,395	14,262 New	14,262 $229,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.